Medicare’s GLP-1 Bridge Is Underway

What We’re Learning and Why It Matters

For years, the Obesity Action Coalition (OAC) has advocated for a simple principle: People affected by obesity deserve access to science-based treatment just as people living with other chronic diseases do.

On July 1, 2026, Medicare took an important step in that direction with the launch of the Medicare GLP-1 Bridge.

The Bridge is a temporary Centers for Medicare & Medicaid Services (CMS) demonstration giving eligible Medicare Part D beneficiaries access to certain GLP-1 medications for chronic weight management. The program is scheduled to continue through December 31, 2027, with eligible beneficiaries paying a $50 copay for a monthly supply of a covered medication.

For people who have faced Medicare coverage barriers, this represents meaningful progress. It is also an opportunity to demonstrate how expanded access to  science-based obesity treatment can work within Medicare.

A New Pathway With a Learning Curve

The Bridge operates differently from traditional Part D coverage. CMS established a separate nationwide process to manage prior authorization, pharmacy claims and payment. Beneficiaries must meet eligibility and clinical criteria, and healthcare providers must submit required prior authorization information.

That means beneficiaries, providers and pharmacies are all learning a new system.

During these first weeks, education and communication are especially important. OAC’s Medicare Bridge Resource Hub can help people understand eligibility, prior authorization, pharmacy processes and other questions.

It is also too early to draw sweeping conclusions about the program’s success. Instead, we are focused on what is working, where barriers are emerging and what can be improved. For OAC, success must ultimately include the experiences of people affected by obesity. Coverage only fulfills its promise when people can actually access appropriate care.

Why Implementation Matters

The Bridge does not solve every access challenge or provide comprehensive obesity care for everyone who needs it. But it is an important policy step in the right direction.

Its significance also extends beyond today’s beneficiaries. CMS has said the Bridge will provide additional information about GLP-1 utilization that can help inform future Medicare policy.  

That means what happens during this demonstration matters. Policymakers and health insurance plans can learn whether beneficiaries can successfully navigate the program, where administrative barriers exist and how access can be improved.

The Bridge alone will not determine the future of obesity medication coverage. However, its experience and evidence can help shape what comes next in Medicare and potentially across the broader health insurance landscape.

The Bridge Cannot Be the Finish Line

People affected by obesity deserve comprehensive, affordable, science-based care without unnecessary barriers. Treatment decisions should be made by individuals and their healthcare providers based on their health needs.

OAC will continue monitoring the Bridge, listening to people affected by obesity and advocating for solutions with Medicare when barriers arise. We will also continue pushing for broader, sustainable access to obesity care.

The Bridge is open. Now we need to make sure it works and use what we learn to keep moving forward.